CCO Oncology Podcast

New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022

Episode Summary

Gain insight into expert faculty perspectives as they discuss recent key studies from EHA 2022 on BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and their potential implications for clinical practice.

Episode Notes

In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: 

• GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLL
• FLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes measurable residual disease–defined therapy duration
• BRUIN: phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
• SHINE: phase III study of ibrutinib with bendamustine + rituximab and rituximab maintenance in older patients with MCL

Presenters:

Othman Al-Sawaf, MD
Faculty of Medicine
University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne 
Düsseldorf, Germany
Visiting Scientist
The Francis Crick Institute
UCL Cancer Institute, University College London 
London, United Kingdom

Lydia Scarfò, MD
Laboratory of B-Cell Neoplasia, Division of Experimental Oncology
Strategic Research Program on CLL
Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele
Milano, Italy

Link to full program:
https://bit.ly/3OQ6634